Clinical Cancer Research, Vol 4, Issue 9 2085-2088, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil

DH Ho, R Pazdur, W Covington, N Brown, YY Huo, Y Lassere and J Kuritani
Department of Clinical Investigation, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Plasma 5-fluorouracil (5-FU) levels were compared in the same patients after approximately equimolar doses (1.9 mmol/ m2/day) of 5-day continuous i.v. infusion of 5-FU (CIFU) and oral administration of a formulation of two combined pharmacological agents, uracil (U) plus N1-(2'-tetrahydrofuryl)-5-fluorouracil (ftorafur or FT), a prodrug of 5-FU. Ten patients received CIFU for 5 days, then, after a week wash-out period, began the 28-day oral UFT regimen, which was given in three daily divided doses. Following 1 h of CIFU, the plasma 5-FU levels reached a steady state of 0.6+/-0.2 microM (mean+/-SD; day 1), which was maintained for the entire 5-day infusion period (0.6+/-0.1 microM). In contrast, the maximum 5-FU concentrations (Cpmax) generated from oral UFT at 1 h after dose administration on days 1 and 5 were 2.1+/-1.5 microM and 2.3+/-1.9 microM, respectively, which were higher than the steady-state levels during CIFU. These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5.2+/-2.4 h (day 1) and 7.2+/-3.9 h (day 5). On day 1 of both regimens, CIFU patients had significantly larger 5-FU area under the concentration versus time curve (AUC0-8h) values (4.4+/-1.3 microM.h) than the AUC value when they received the UFT regimen (2.6+/-1.7 microM.h; P = 0.02). However, by day 5, there were no significant differences between AUC0-8 h values in patients receiving CIFU and UFT, respectively (4.8+/-1.5 microM.h versus 3.8+/-2.2 microM.h; P = 0.30)]. On day 5, the average concentration of the metabolite 5-FU at steady-state (Css,aver) within dose interval of 8 h (0.48+/-0.28 microM) for the oral UFT treatment is comparable with the Cpss values of 5-FU from CIFU-treated patients. The post-UFT generated 5-FU pharmacokinetic parameters (higher Cp(mx, comparable Css,aver, equal AUC values, and longer apparent t1/2,beta of 5-FU) may make oral UFT a preferred method of delivering this fluoropyrimidine over CIFU. In addition, oral UFT would eliminate the incidence of venous thrombosis and catheter-related infections sometimes seen in patients treated with CIFU. Furthermore, the convenience and decreased cost of oral administration may be preferable for many patients, particularly those receiving 5-FU for palliation.

This article has been cited by other articles:

				H.-Y. Zhao, A. Ooyama, M. Yamamoto, R. Ikeda, M. Haraguchi, S. Tabata, T. Furukawa, X.-F. Che, S. Zhang, T. Oka, et al. Molecular Basis for the Induction of an Angiogenesis Inhibitor, Thrombospondin-1, by 5-Fluorouracil Cancer Res., September 1, 2008; 68(17): 7035 - 7041. [Abstract] [Full Text] [PDF]

				E. Casado, P. Pfeiffer, J. Feliu, M. Gonzalez-Baron, L. Vestermark, and H. A. Jensen UFT (tegafur-uracil) in rectal cancer Ann. Onc., August 1, 2008; 19(8): 1371 - 1378. [Abstract] [Full Text] [PDF]

				N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]

				H. S. Hochster, W. Luo, E. C. Popa, B. T. Lyman, M. Mulcahy, P. A. Beatty, and A. B. Benson Phase II Study of Uracil-Tegafur With Leucovorin in Elderly (>= 75 years old) Patients With Colorectal Cancer: ECOG 1299 J. Clin. Oncol., December 1, 2007; 25(34): 5397 - 5402. [Abstract] [Full Text] [PDF]

				N. Tomita, M. Fukunaga, S. Okamura, H. Narahara, N. Uedo, R. Ishihara, H. Ishida, H. Furukawa, M. Gotoh, and H. Takiuchi Phase I/II Study of CPT-11 plus UFT in Patients with Advanced/Recurrent Colorectal Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102 Jpn. J. Clin. Oncol., July 1, 2007; 37(7): 521 - 527. [Abstract] [Full Text] [PDF]

				A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2933 - 2943. [Abstract] [Full Text] [PDF]

				M. Ikeda, T. Okusaka, H. Ueno, C. Morizane, J. Furuse, and H. Ishii A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 439 - 443. [Abstract] [Full Text] [PDF]

				M. Nakagawa, F. Tanaka, N. Tsubota, M. Ohta, M. Takao, H. Wada, and On behalf of the West Japan Study Group for Lung C A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study Ann. Onc., January 1, 2005; 16(1): 75 - 80. [Abstract] [Full Text] [PDF]

				C. Fernandez-Martos, J. Aparicio, C. Bosch, M. Torregrosa, J. M. Campos, S. Garcera, J. M. Vicent, I. Maestu, M. A. Climent, J. L. Mengual, et al. Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study With 3 Years' Follow-Up J. Clin. Oncol., August 1, 2004; 22(15): 3016 - 3022. [Abstract] [Full Text] [PDF]

				Y. Ichinose, Y. Nakai, S. Kudoh, H. Semba, S. Yoshida, T. Nukiwa, H. Yamamoto, Y. Yamane, and H. Niitani Uracil/Tegafur Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Multi-institutional Phase II Trial Clin. Cancer Res., July 1, 2004; 10(13): 4369 - 4373. [Abstract] [Full Text] [PDF]

				G. J. Peters, P. Noordhuis, C. J. van Groeningen, G. Giaccone, U. Holwerda, D. Voorn, A. Schrijvers, J. H. Schornagel, J. H. Beijnen, P. Fumoleau, et al. The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors Clin. Cancer Res., June 15, 2004; 10(12): 4072 - 4076. [Abstract] [Full Text] [PDF]

				H. Kato, Y. Ichinose, M. Ohta, E. Hata, N. Tsubota, H. Tada, Y. Watanabe, H. Wada, M. Tsuboi, N. Hamajima, et al. A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung N. Engl. J. Med., April 22, 2004; 350(17): 1713 - 1721. [Abstract] [Full Text] [PDF]

				J.-S. Chen, T.-S. Yang, Y.-C. Lin, and Y.-Y. Jan A Phase II Trial of Tegafur-Uracil Plus Leucovorin (LV) in the Treatment of Advanced Biliary Tract Carcinomas Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 353 - 356. [Abstract] [Full Text] [PDF]

				J. Feliu, R. Mel, P. Borrega, L. Lopez Gomez, P. Escudero, J. Dorta, J. Castro, S. E. Vazquez-Estevez, M. Bolanos, E. Espinosa, et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas Ann. Onc., November 1, 2002; 13(11): 1756 - 1762. [Abstract] [Full Text] [PDF]

				T.-S. Yang, J.-Y. Wang, R. Tang, K.-C. Hsu, and J.-S. Chen Oral Uracil/Ftorafur (UFT) Plus Leucovorin as First-line Chemotherapy and Salvage Therapy with Weekly High-dose 5-Fluorouracil/Leucovorin for the Treatment of Metastatic Colorectal Cancer Jpn. J. Clin. Oncol., September 1, 2002; 32(9): 352 - 357. [Abstract] [Full Text] [PDF]

				J.-Y. Douillard, P. M. Hoff, J. R. Skillings, P. Eisenberg, N. Davidson, P. Harper, M. D. Vincent, B. C. Lembersky, S. Thompson, A. Maniero, et al. Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3605 - 3616. [Abstract] [Full Text] [PDF]

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				S. J. Cohen, C. G. Leichman, G. Yeslow, M. Beard, A. Proefrock, B. Roedig, B. Damle, S. P. Letrent, A. P. DeCillis, and N. J. Meropol Phase I and Pharmacokinetic Study of Once Daily Oral Administration of S-1 in Patients with Advanced Cancer Clin. Cancer Res., July 1, 2002; 8(7): 2116 - 2122. [Abstract] [Full Text] [PDF]

				J. Feliu, J. Calvillo, A. Escribano, J. de Castro, M. E. Sanchez, A. Mata, E. Espinosa, A. Garcia Grande, A. Mateo, and M. Gonzalez Baron Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy Ann. Onc., May 1, 2002; 13(5): 730 - 736. [Abstract] [Full Text] [PDF]

				F. Mayer, J. T. Hartmann, J. von Pawel, J. Beck, M. Schroeder, I. Boehlke, L. Kanz, and C. Bokemeyer A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors Ann. Onc., May 1, 2002; 13(5): 755 - 759. [Abstract] [Full Text] [PDF]

				B. J. Fueger, G. Hamilton, M. Raderer, T. Pangerl, T. Traub, P. Angelberger, G. Baumgartner, R. Dudczak, and I. Virgolini Effects of Chemotherapeutic Agents on Expression of Somatostatin Receptors in Pancreatic Tumor Cells J. Nucl. Med., December 1, 2001; 42(12): 1856 - 1862. [Abstract] [Full Text] [PDF]

				G. J. Peters, C. J. van Groeningen, G. Giaccone, and R. M. White Jr Fluorouracil (5FU) Pharmacokinetics in 5FU Prodrug Formulations With a Dihydropyrimidine Dehydrogenase Inhibitor J. Clin. Oncol., November 15, 2001; 19(22): 4267 - 4269. [Full Text]

				R. M. White Correct Fluorouracil (5-FU) Half-Life Comparator for a 5-FU Prodrug Plus a Dihydropyrimidine Dehydrogenase Inhibitor J. Clin. Oncol., June 1, 2001; 19(11): 2970 - 2970. [Full Text] [PDF]

				P. M. Hoff, N. Janjan, E. D. Saad, J. Skibber, C. Crane, Y. Lassere, K. R. Cleary, S. Benner, J. Randolph, J. L. Abbruzzese, et al. Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer J. Clin. Oncol., October 20, 2000; 18(20): 3529 - 3534. [Abstract] [Full Text] [PDF]

				K. Hirata, N. Horikoshi, K. Aiba, M. Okazaki, R. Denno, K. Sasaki, Y. Nakano, H. Ishizuka, Y. Yamada, S. Uno, et al. Pharmacokinetic Study of S-1, a Novel Oral Fluorouracil Antitumor Drug Clin. Cancer Res., August 1, 1999; 5(8): 2000 - 2005. [Abstract] [Full Text] [PDF]